Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology director Leonard E. Post reported coordinated stock transactions. On June 24, 2026, he sold 5,000 shares of Common Stock in an open-market transaction at $70.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026.
On the same date, he exercised a director stock option to acquire 5,000 common shares at an exercise price of $0.60 per share. After these moves, he directly owned 5,000 common shares and held 106,077 director stock options expiring on July 8, 2028, indicating an exercise-and-sell pattern with a substantial remaining option position.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the sale of 5,000 shares of Common Stock. The filing lists an Exercise of Stock Options on 06/24/2026 for 5,000 shares to be settled for cash. The filing also discloses recent 10b5-1 executions by Leonard Post: 5,000 shares sold on 06/22/2026 for $325,000 and 1,000 shares sold on 06/04/2026 for $54,500.
CG Oncology director Leonard E. Post reported an option exercise and share sale. On June 22, 2026, he exercised options to acquire 5,000 shares of common stock at $0.60 per share and sold 5,000 shares at $65.00 in an open-market transaction. The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he reported no directly held common shares but retained 111,077 director stock options with a $0.60 exercise price expiring on July 8, 2028.
CGON filing a Rule 144 notice reporting the proposed sale of 6,000 common shares by an affiliated account on 06/22/2026. The filing also records a 10b5-1 sale of 1,000 common shares on 06/04/2026 for $54,500.00. The transaction method for the 6,000 shares is listed as exercise of stock options with cash used for the exercise.
CG Oncology, Inc. director James Mulay reported an exercise-and-sell transaction in company stock. He exercised options for a total of 1,964 shares of Common Stock at strike prices of $12.59 and $3.72 per share, then sold 1,964 shares in open-market trades at $60.12 per share.
The options exercised were Director Stock Options with expiration dates in 2033. A footnote states the sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026, indicating these dispositions were scheduled in advance rather than timed discretionarily.
CG Oncology, Inc. reported the results of its 2026 annual stockholder meeting. As of the April 7, 2026 record date, 88,009,980 shares of common stock were outstanding and entitled to vote. Stockholders elected Class II directors Christina Rossi and Victor Tong, Jr. to terms running until the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In advisory votes, stockholders approved the compensation of named executive officers and expressed a preference for holding future advisory votes on executive pay every year, and the company will follow an annual frequency.
CG Oncology director Brian Guan-Chyun Liu received a grant of stock options for 9,354 shares of common stock. These Director Stock Options give him the right to buy shares at an exercise price of $56.09 per share and expire on June 3, 2036.
The options vest over time: 1/12 of the total vests monthly after the June 4, 2026 grant date, as long as he continues serving the company. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion will vest on that meeting date.
CG Oncology, Inc. director Victor Edward Tong Jr. received a grant of stock options covering 9,354 shares of common stock. The options have an exercise price of $56.09 per share and expire on June 3, 2036.
These options vest in 12 equal monthly installments after June 4, 2026, the grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested portion vests on the meeting date, contingent on his continued service.
CG Oncology, Inc. director James Mulay received a grant of stock options covering 9,354 shares of common stock. These options have an exercise price of $56.09 per share and expire on June 3, 2036.
Following this grant, Mulay holds options for 9,354 shares directly. According to the vesting terms, 1/12 of the options vest monthly after June 4, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs before the first anniversary, subject to his continuous service.
CG Oncology, Inc. director Leonard E. Post reported an exercise-and-sale transaction plus a new option grant. He exercised 1,000 stock options at $0.60 per share and sold 1,000 common shares at $54.50 per share under a pre-arranged Rule 10b5-1 trading plan. He also received a fully vested grant of 9,354 director stock options with a $56.09 exercise price, while another option grant for 9,354 shares vests monthly after June 4, 2026. Following these transactions, he holds 1,000 common shares and 116,077 director stock options.